التهاب الجلد التأتبي المعتدل إلى الشديد عندما لم يحقق العلاج المناعي بالمستضدات سيطرة كافية

References

DOI: 10.1016/j.anai.2023.11.009

• Recommendation 16: In patients 6 months of age or older with moderate-severe AD refractory, intolerant, or unable to use mid-potency or greater topical treatment, the JTF panel recommends adding dupilumab over continued standard topical treatment without dupilumab (strong recommendation, high-certainty evidence).
• In patients 12 years of age or older with moderate-severe AD refractory, intolerant, or unable to use mid-potency topical treatment, the JTF panel recommends adding tralokinumab over continued topical treatment without tralokinumab (strong recommendation, high-certainty evidence).
• The linked systematic review and NMA of 149 RCTs evluating 75 interventions in 28,686 patients revealed that compared with continued standard topical treatment alone, adding dupilumab led to large improvements in multiple patient-important outcomes (Fig 5 presents an abbreviated summary of findings from systemic NMA) including AD severity, judged either by patients or clinicians, itch, sleep disturbance, AD-related quality of life, without an increase in serious adverse events or adverse events leading to discontinuation.